

AD _____

Award Number: W81XWH-10-1-0341

TITLE: Genetic Modifiers of Ovarian Cancer

PRINCIPAL INVESTIGATOR: Fergus Couch

CONTRACTING ORGANIZATION: Mayo Clinic
Rochester, MN 55905

REPORT DATE: June 2011

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-06-2011		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 15 MAY 2010 - 14 MAY 2011	
4. TITLE AND SUBTITLE Genetic Modifiers of Ovarian Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-10-1-0341	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Fergus Couch E-Mail: couch.fergus@mayo.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mayo Clinic Rochester, MN 55905				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Individuals with germline mutations in BRCA1 have an elevated but incomplete risk of developing ovarian cancer suggesting the presence of genetic modifiers of ovarian cancer in this population. A genome wide association study (GWAS) for ovarian cancer in BRCA1 mutation carriers was initiated in an effort to identify common genetic variants that modify ovarian cancer risk. The discovery phase of the study has been completed. A replication phase of the 6,000 most significantly associated variants is underway. In a separate study, variants in a 19p13.1 locus have been identified as modifiers of both breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.					
15. SUBJECT TERMS BRCA1, ovarian cancer, genome wide association study, association study					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	9	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
BODY.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusion.....	7
References.....	7
Appendices.....	9

Introduction:

Inactivating mutations in the *BRCA1* tumor suppressor gene have been detected in approximately 10% of all ovarian cancers. Individuals with germline mutations in *BRCA1* have a substantially increased risk of developing ovarian cancer as compared to the general population, with an estimated cumulative risk of ovarian cancer by age 70 of 39% (1). These findings indicate that although *BRCA1* mutation carriers are at high risk for developing ovarian cancer, a sizeable proportion of women who carry a deleterious mutation will not develop this disease. In addition, the findings show that there is considerable variation in the age of onset of ovarian cancer in this population. This variable penetrance and age of onset of ovarian cancer suggest that there are additional genetic and environmental factors that modify the age specific risk of ovarian cancer for *BRCA1* mutation carriers. Common genetic variants that are associated with the risk of ovarian cancer have recently been identified through candidate gene and genome wide association studies in the general population (2-4). This suggests that common genetic variants may also modify ovarian cancer risk in carriers of *BRCA1* mutations. Identification of these genetic risk factors may prove useful for identifying those *BRCA1* carriers at elevated or lowered risk of ovarian cancer compared to the average *BRCA1* carrier. Women at increased risk may subsequently benefit from enhanced screening or certain prevention measures such as prophylactic oophorectomy, whereas women at lowered risk may be able to avoid these types of intervention (5). Thus, we proposed a study aimed at identifying genetic risk factors for ovarian cancer in *BRCA1* mutation carriers through a genome wide association study in *BRCA1* mutation carriers. The overall intent was to complete a genome wide association study of *BRCA1* carriers, validate candidate risk modifiers, to assess the contribution of these modifiers to sporadic ovarian cancer and to develop risk prediction models.

Body

Aim 1: To conduct a genome-wide association scan in 1,000 *BRCA1* carriers with ovarian cancer and 1,000 age-matched unaffected *BRCA1* carriers.

Genome Wide Association Study (GWAS)

As described in Preliminary data we conducted a Stage 1 GWAS using Human660W-Quad arrays on 1250 *BRCA1* mutation carriers diagnosed with breast cancer and 12500 unaffected. The 1250 unaffected included 361 diagnosed with ovarian cancer. Subsequently we collected and genotyped an additional 434 *BRCA1* mutation carriers diagnosed with ovarian cancer on Human660W-Quad arrays. In addition we acquired GWAS genotype data for 120 additional *BRCA1* mutation carriers affected with ovarian cancer from collaborators. Together this resulted in GWAS genotype data from 915 *BRCA1* mutation carriers diagnosed with ovarian cancer.

Genotyping calls were obtained using the standard Illumina calling algorithm incorporated in the BeadStudio software. As expected gender checks using PLINK software failed to identify male *BRCA1* carriers. Duplicates were identified by identify-by-descent analyses and were removed. Quality control thresholds of >95% variant call rates and >95% sample call rates were applied. Variant with minor allele frequency <0.05 were excluded. In addition single nucleotide polymorphisms (SNPs) displayed divergence from Hardy Weinberg equilibrium $p < 1 \times 10^{-7}$ were removed. Final analyses included 897 *BRCA1* mutation carriers with ovarian cancer and approximately 540,000 SNPs. Genetic relatedness among samples from different countries and ethnicities can introduce heterogeneity into association studies and cause important SNPs to be overlooked. While this study was restricted to Caucasian *BRCA1* carriers the study did include DNA samples from many countries. To account for population stratification, the genotyping data in combination with HapMap data (CEU, Yoruban, Han Chinese populations) on 40,000 SNPs with known phase were analyzed by Eigenstrat. A total of 17 individuals were excluded because of non-caucasian admixture of between 15% and 25%. In collaboration with Drs. Douglas Easton and Antonis Antoniou at the University of Cambridge, we evaluated associations with both breast and ovarian cancer using a retrospective likelihood model. This accounts for the age extremes of affected and unaffected and also applies age related penetrance estimates for *BRCA1* carriers. Carriers were censored at age of onset of disease for those affected with breast or ovarian cancer and age of last follow up or age at

prophylactic mastectomy/oophorectomy for those with no cancer diagnosis. Analyses were adjusted for Country of origin because samples from 26 different centers in 18 countries were included in the study. SNPs used in the study were listed in order of significance of associations with breast cancer and separately for ovarian cancer. For ovarian cancer, no SNPs showed genome wide significance ($p < 1 \times 10^{-7}$). However, 10 exhibited associations of $p < 1 \times 10^{-5}$ and 37 has associations of $p < 1 \times 10^{-4}$. Interestingly, SNPs from two loci (BCN2 and TIPARP) have been found to exhibit genome wide associations with ovarian cancer in the general population (2, 3). When we examined the results from the BRCA1 ovarian cancer GWAS we found that rs1339552 on chromosome 9 in BCN2 ($p = 1.9 \times 10^{-5}$) and rs7651446 from TIPARP on chromosome 3 ($p = 1.7 \times 10^{-4}$) were highly significantly associated with ovarian cancer. Since the lack of genome wide significance is likely due to the limited number of BRCA1 mutation carriers, these loci can be considered genetic risk factors for ovarian cancer in BRCA1 mutation carriers.

These efforts complete the proposed studies in Aim, which include Task 1-4.

Aim 2: To further evaluate observed associations between ovarian cancer risk and SNPs implicated in Aim 1 by genotyping 1,500 *BRCA1* ovarian cancer cases and 1,500 unaffected *BRCA1* carriers.

Validation of Chromosome 19p13.1 associations

Aim 2 of this proposal is focused on validating findings from Stage 1 of the GWAS. Here we describe our efforts to date on this part of the project. Initially we conducted validation studies of candidate SNPs from breast cancer association studies in BRCA1 mutation carriers. The rationale was that because both breast and ovarian cancer occur in BRCA1 mutation carriers, SNPs that modify risk of both breast and ovarian cancer may exist along with SNPs that specifically modify ovarian cancer risk. In our breast studies we further evaluated the 89 most significantly associated SNPs from the breast cancer GWAS in BRCA1 mutation carriers in an additional 5986 *BRCA1* mutation carriers (3012 unaffected, 2974 affected). In the combined analysis of stage 1 and stage 2 samples there was strong evidence of association with breast cancer for five SNPs from a single locus on chromosome 19p13.1 ($P = 2.3 \times 10^{-9}$ to 3.9×10^{-7}). The minor alleles of rs8170 and rs4808611 were associated with an increase in breast cancer risk for *BRCA1* mutation carriers (per allele HR=1.26, 95%CI: 1.17-1.35 for both SNPs) (6). There was no evidence of heterogeneity in the HR estimates for any of the SNPs among the countries of residence. The most strongly associated SNPs are located in a 35kb region containing three genes, *ABHD8* (abhydrolase domain containing 8), *ANKLE1* (ankyrin repeat and LEM domain containing 1), and *C19orf62*. The *C19orf62* gene, which encodes MERIT40 (Mediator of Rap80 Interactions and Targeting 40 kD), is a plausible genetic modifier of breast cancer in *BRCA1* mutation carriers because MERIT40 interacts with BRCA1 in a protein complex that is required for recruitment and retention of the BRCA1/BARD1 ubiquitin ligase at sites of DNA damage.

In this first analysis of <8000 *BRCA1* mutation carriers, no association with ovarian cancer was identified for any of the five SNPs from the 19p13.1 locus. However, we subsequently conducted a more complete genotyping study in 12,599 *BRCA1* and 7,132 *BRCA2* mutation carriers, which included 1,465 *BRCA1* mutation carriers and 453 *BRCA2* mutation carriers with ovarian cancer. To assess the influence of these SNPs on ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers we used a competing risk analysis that accounted for the effects on breast and ovarian cancer in parallel. In this competing risk analysis rs67397200 at 19p13.1 was strongly associated with ovarian cancer risk in *BRCA1* (HR=1.16; 95%CI 1.05-1.29; $p = 3.8 \times 10^{-4}$) and *BRCA2* (HR=1.30; 95%CI 1.10-1.52; $p = 1.8 \times 10^{-3}$) mutation carriers. Similar results were obtained for rs8170 at 19p13.1 (Table 1). Thus, none of the SNPs associated with breast cancer risk in *BRCA1* or *BRCA2* mutation carriers have been associated with ovarian cancer risk. Similarly, none of the SNPs in the BCN2 and TIPARP loci that are associated with ovarian cancer risk in *BRCA1* mutation carriers have been associated with breast cancer risk in *BRCA1* carriers. Furthermore, in the general population, only SNPs in the 8q24 locus are known to influence both breast and ovarian cancer, and these appear to be independent disease-specific effects. Here we report the first variants (from the 19p13.1 locus) found to influence both breast and ovarian cancer risk in either *BRCA1* or *BRCA2* mutation carriers.

Table 1. Associations with SNPs and breast and ovarian cancer risk using a competing risk analysis model among *BRCA1* and *BRCA2* mutation carriers of European ancestry

SNP/ Gene		Alleles	Unaffected N (%)	Breast Cancer N (%)	Ovarian Cancer N (%)	Breast Cancer			Ovarian Cancer		
						HR	95% CI	p-value	HR	95% CI	p-value
rs8170 – 19p13.1											
BRCA1	GG		2972 (67.9)	3730 (63.3)	923 (66.0)	1.00			1.00		
	AG		1269 (29.0)	1936 (32.9)	434 (31.0)	1.26	1.17 – 1.36		1.23	1.08 – 1.42	
	AA		139 (3.2)	224 (3.8)	42 (3.0)	1.34	1.10 – 1.63		1.04	0.72 – 1.50	
	per allele					1.22	1.14 – 1.30	2.1×10 ⁻⁴	1.15	1.03 – 1.29	0.015
BRCA2	GG		1788 (67.0)	2494 (68.2)	266 (62.2)	1.00			1.00		
	AG		796 (29.9)	1024 (28.0)	137 (32.0)	0.95	0.85 – 1.05		1.17	0.93 – 1.47	
	AA		83 (3.1)	138 (3.8)	25 (5.8)	1.37	1.05 – 1.80		2.72	1.65 – 4.48	
	per allele					1.02	0.94 – 1.12	0.62	1.34	1.12 – 1.62	1.9×10 ⁻³
rs67397200 – 19p13.1											
BRCA1	CC		1903 (51.5)	2436 (46.0)	652 (49.7)	1.00			1.00		
	GC		1498 (40.5)	2381 (44.9)	540 (41.2)	1.28	1.18 – 1.38		1.16	1.01 – 1.33	
	GG		298 (8.1)	484 (9.1)	120 (9.2)	1.33	1.16 – 1.53		1.36	1.07 – 1.73	
	per allele					1.20	1.13 – 1.27	4.5×10 ⁻¹⁰	1.16	1.05 – 1.29	3.8×10 ⁻⁴
BRCA2	CC		1363 (50.5)	1866 (50.7)	194 (45.2)	1.00			1.00		
	GC		1123 (41.6)	1489 (40.5)	184 (42.9)	0.96	0.87 – 1.06		1.15	0.92 – 1.44	
	GG		214 (7.9)	323 (8.8)	51 (11.9)	1.18	0.99 – 1.41		1.95	1.37 – 2.77	
	per allele					1.03	0.96 – 1.11	0.39	1.30	1.10 – 1.52	1.8×10 ⁻³

GWAS validation studies

The original intent for this project was to further evaluate the 384 most significantly associated SNPs from the *BRCA1* ovarian cancer GWAS in 3,000 additional *BRCA1* mutation carriers including 1,500 with ovarian cancer. However, in 2010 we were provided the opportunity to participate in a large multi-consortium replication study. Specifically, we designed a SNP array (iCOGS) containing 211,000 candidate SNPs from GWAS of various tumor types. A total of 35,000 candidate SNPs were selected from the *BRCA1* GWAS including 6,000 from the *BRCA1* Ovarian Cancer GWAS. Testing of the arrays showed that 204,000 of the SNPs yielded good quality genotyping. The other 7,000 SNPs were excluded from further consideration.

We proposed to genotype 14,000 DNA samples from *BRCA1* mutation carriers on these arrays in contrast to the 3,000 originally planned for Stage 2 of the ovarian cancer GWAS. Investigators in 52 groups from around the world have provided non-amplified genomic DNA samples from approximately 15,000 female *BRCA1* mutation carriers including approximately 1,400 with ovarian cancer. Each of these samples was evaluated for DNA quality by conducting picogreen and E-gel (Invitrogen) analysis. Samples with low levels of DNA (<250ng available) or with degraded DNA, identified as smearing on Egel analysis, were excluded (n=1,200). A total of 12,700 Caucasian, 150 Malaysian and 204 Hong Kong DNA samples were identified as useful for further validation studies and were subjected to genotyping on the iCOGS array. Genotyping has been ongoing at the Genotype Shared Resource at the Mayo Clinic and is almost complete. Once complete, rigorous quality control measures will be applied as for the GWAS. Associations with breast and ovarian cancer in *BRCA1* mutation carriers will be evaluated using the retrospective likelihood model.

Based on these efforts we have now completed Tasks 5 to 8 from Aim 2. The next step is to conduct Task 9, which involves analysis of the genotyping data from the iCOGS array.

Key Research Accomplishments

- Completed a GWAS for ovarian cancer in BRCA1 mutation carriers and identified candidate ovarian cancer risk modifier loci.
- Demonstrated that common variants from a chromosome 19p13.1 locus are associated with ovarian cancer as well as breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Reportable Outcomes

None

Conclusion

In summary, we have completed the discovery phase of an ovarian cancer GWAS for BRCA1 mutation carriers, and the genotyping for an extended replication phase of the most significant findings from the study. In an interim analysis of these data we have also successfully identified a 19p13.1 locus that is associated with ovarian cancer risk as well as breast cancer risk for BRCA1 mutation carriers and BRCA2 mutation carriers. Other variants that have been associated with risk of breast cancer in BRCA1 and BRCA2 mutation carriers have shown potential for determination of individual risk of breast cancer in this population. Thus, the 19p13.1 locus that is associated with ovarian cancer risk in BRCA1 carriers and other loci that are expected to be identified through the validation of the GWAS are expected to be useful for improved risk assessment of ovarian and breast cancer risk for BRCA1 and perhaps BRCA2 mutation carriers. In addition, by identifying the underlying causative variants in these loci we expect to develop a greater understanding of the initiation factors involved in breast cancer. For this reason we recommend extending this study to fine mapping efforts of loci associated with ovarian cancer in this population

References

1. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD and Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *Br J Cancer*. 98:1457-66, 2008.
2. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dork T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Durst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubinski J, Lurie G, McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BA, Pearce CL, Ness RB, Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PD and Gayther SA. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet*. 41:996-1000, 2009.
3. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeny LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT,

- Dork T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, Beesley J, Webb PM, Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despiere E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Durst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA and Pharoah PD. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet.* 42:874-9, 2010.
4. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeny LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Durst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despiere E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD and Gayther SA. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet.* 42:880-4, 2010.
 5. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL and Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *Jama.* 304:967-75, 2010.
 6. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, Hardouin A, Berthet P, Hogervorst FB, Rookus MA, Jager A, van den Ouweland A, Hoogerbrugge N, van der Luijt RB, Meijers-Heijboer H, Gomez Garcia EB, Devilee P, Vreeswijk MP, Lubinski J, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Gorski B, Cybulski C, Spurdle AB, Holland H, Goldgar DE, John EM, Hopper JL, Southey M, Buys SS, Daly MB, Terry MB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Preisler-Adams S, Arnold N, Niederacher D, Sutter C, Domchek SM, Nathanson KL, Rebbeck T, Blum JL, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Blank SV, Friedman E, Kaufman B, Laitman Y, Milgrom R, Andrulis IL, Glendon G, Ozelik H, Kirchhoff T, Vijai J, Gaudet MM, Altshuler D, Guiducci C, Loman N, Harbst K, Rantala J, Ehrencrona H, Gerdes AM, Thomassen M, Sunde L, Peterlongo P, Manoukian S, Bonanni B, Viel A, Radice P, Caldes T, de la Hoya M, Singer CF, Fink-Retter A, Greene MH, Mai PL, Loud JT, Guidugli L, Lindor NM, Hansen TV, Nielsen FC, Blanco I, Lazaro C, Garber J, Ramus SJ, Gayther SA, Phelan C, Narod S, Szabo CI, Benitez J, Osorio A, Nevanlinna H, Heikkinen T, Caligo MA, Beattie MS, Hamann U, Godwin AK, Montagna M, Casella C, Neuhausen SL, Karlan BY, Tung N, Toland AE, Weitzel J, Olopade O, Simard J, Soucy P, Rubinstein WS, Arason A, Rennert G, Martin NG, Montgomery GW, Chang-Claude J, Flesch-Janys D, Brauch H, Severi G, Baglietto L, Cox A, Cross SS, Miron P, Gerty SM, Tapper W, Yannoukakos D, Fountzilas G, Fasching PA, Beckmann MW, Dos Santos Silva I, Peto J, Lambrechts D, Paridaens R, Rudiger T, Forsti A, Winqvist R, Pylkas K, Diasio

RB, Lee AM, Eckel-Passow J, Vachon C, Blows F, Driver K, Dunning A, Pharoah PP, Offit K, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF and Couch FJ. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet.* 42:885-92, 2010.

Appendices

None.